摘要
背景与目的:舒尼替尼治疗肾癌已取得显著疗效,本研究旨在初步探讨舒尼替尼治疗晚期肾癌的有效性及安全性。方法:晚期肾癌患者36例,其中单发转移16例,其余为全身多发转移病灶,均经穿刺病理证实为肾癌。采用标准4/2治疗方案:舒尼替尼50 mg,每天1次。口服,服药4周停药2周为1个周期,持续至患者疾病进展或出现不可耐受的不良反应,至少2个周期进行1次疗效评价。结果:随访截止至2012年7月,可评价疗效病例29例,疾病进展(progressive disease,PD)5例、部分缓解(partial response,PR)6例、完全缓解(complete response,CR)1例,疾病稳定(stable disease,SD)17例,疾病控制率(DCR=CR+PR+SD)为82.8%(24/29),客观反应率(ORR=CR+PR)为24.1%(7/29),因疾病进展死亡5例(17.2%),中位无进展生存期(progression-free survival,PFS)与总生存期(overall survival,OS)尚未达到。常见不良反应主要有乏力21例(58.3%)、皮肤黄染17例(47.2%)、手足皮肤反应18例(50%)、高血压16例(44.4%)、甲状腺功能减退8例(22.2%)、腹泻10例(27.8%)、贫血9例(25%)、中性粒细胞减少9例(25%)、血小板减少7例(19.4%),3、4级不良反应有手足皮肤反应2例(6%),高血压1例(3%),中性粒细胞减少3例(8%),血小板减少2例(6%)。多数为轻度不良反应,经对症治疗后均可缓解。结论:舒尼替尼治疗晚期肾癌有效,严重不良反应较少,耐受性及安全性良好。
Background and purpose： There is significant efficacy in the treatment of renal cell carcinoma for sunitinib. This article aimed to investigate preliminarily the efficacy and safety of advanced renal cell carcinoma treated with sunitinib. Methods： A total number of 36 patients with advanced renal cell carcinoma were enrolled, including 16 cases of solitary metastases and the rest of systemic multiple metastases, all the patients were confirmed by biopsy. Sunitinib was administered in standard 4/2 regimens： 50 mg once a day orally, taking 4 weeks, stopping 2 weeks, 6 weeks per 1 cycle, and continued until disease progression or occurrence of intolerable adverse reactions, and had an efficacy evaluation at least 2 cycles. Results： The follow-up ended in Jul. 2012, 29 patients could be evaluated efficacy, 5（17.2%） patients dead, 5 patients developed progressive disease, 6 patients achieved partial remission, 1 patient achieved complete remission, 17 patients demonstrated stable disease, the disease control rate was 82.8% （24/29）, objective response rate was 24.1% （7/29）. The median progression-free survival and overall survival has not yet reached. The follow-up time was ranged from 3 to 28 months. Common adverse reactions were mainly fatigue,yellowish discoloration of skin, hand-foot skin reaction, hypertension, hypothyroidism, diarrhea, anemia, neutropenia, thrombocytopenia, 3-4 adverse events were hand-foot skin reaction （11.5%）, hypertension, thrombocytopenia and neutropenia. Mostly mild adverse reactions after symptomatic treatment could be alleviated, did not affect the medication. Conclusion： Sunitinib was efficacious in the treatment of advanced kidney cancer, had fewer serious adverse reactions and good tolerability and safety.
出处
《中国癌症杂志》
CAS
CSCD
北大核心
2013年第3期235-238,共4页
China Oncology
关键词
肾癌
转移癌
舒尼替尼
不良反应
Renal cell carcinoma
Metastatic
Sunitinib
Adverse event
